Clinical Trial Search

Primary: Time From Start of Administration of 4.0 mg/kg Sugammadex to Recovery of the T4/T1 Ratio to 0.9 Measured by a TOF-Watch® SX — 1.5 Minutes

Primary: Comparison of ECOM Impedance and Thermodilution Cardiac Output Measurements — 0.31 liters/min

Primary: Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale…

Primary: Acute SAE Rate — 12.0 percentage of subjects with ≥ 1 SAE

Primary: Incidence of RSV Hospitalization (Includes Deaths by RSV) — 62; 46 Participants

Primary: Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12 — 0.289; 0.359; 0.283 Liters — p=0.244

Primary: Percentage Surface Microhardness Recovery of Test Dentifrices Relative to Placebo Dentifrice — 30.72; 29.49; 28.29; 25.13 %SMHR — p=<0.0001

Primary: Adjusted Mean Change in HbA1c Levels — -0.41; -0.45; -0.06 Percent — p=<0.0001

Primary: Adjusted Mean Change in HbA1c Levels — -0.38; 0.08 Percent — p=<0.0001

Primary: 10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation — 25.5; 49.0; 43.6; 50.7 percentage of subjects

Primary: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement) — 9; 6 participants — p=0.39

Primary: Adjusted Mean Change in HbA1c Levels — -0.33; 0.07 Percent — p=<0.0001

Primary: Adjusted Mean Change in HbA1c Levels — -0.30; -0.75; -0.82; -0.90 Percent — p=<0.0001

Primary: Progression-Free Survival (PFS): Independent Radiologist Review — 5.8; 7.3 Months — p=0.0190

Primary: Adjusted Mean Change in HbA1c Levels — -0.52; -0.52 percent — p=<0.0001